Myeloma

Mariska Hargitay discusses her father's myeloma, hope from research and the importance of community and caregivers for patients.

Mezigdomide, Kyprolis and dexamethasone cut progression risk by 52% in relapsed or refractory multiple myeloma.

Discover how a multiple myeloma survivor manages treatment and daily anxiety through Qigong, rituals and self-care.

Elrexfio improved progression-free survival in multiple myeloma, helping patients live longer without disease worsening in a phase 3 trial.

A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges of living with cancer.

FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after prior therapy, based on trial results showing longer disease control.

Learn how survivor Julie Cohen navigated high-risk multiple myeloma, failed treatments and the vital role of nurse navigators in chronic cancer care.

MGUS is a precursor condition that requires monitoring rather than aggressive intervention.

Daily practices help one writer find calm and stability while living with multiple myeloma.

ACS data show rising five-year survival and shifting cancer care toward survivorship, access to novel therapies and prevention as incidence climbs.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients live longer after cancer

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August.

Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options.

Oral KTX-1001 achieved 40% disease control in phase 1 trials, offering a new targeted therapy for aggressive t(4;14) translocation multiple myeloma.

Anxiety is not just an emotion but a presence with its own heartbeat, its own spirit, waiting in ambush for moments of vulnerability.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies.

CURE recently spoke with CEPHEUS study investigator Dr. Saad Z. Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center.

Smoldering multiple myeloma is a complex, intermediary stage of plasma cell disorders that requires a nuanced approach to care.

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

Being a multiple myeloma care partner involves significant logistical and emotional challenges.

Shared decision-making empowers multiple myeloma patients and their care partners to actively collaborate with the medical team on treatment choices.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Modern multiple myeloma treatment often involves complex combination therapies, which significantly impact daily life for patients and care partners.

Ensuring medication adherence for multiple myeloma treatment involves both practical systems and a patient-centered mindset.